Oral Clonidine Liquid Composition for Room-Temperature Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing clonidine formulations for oral administration, particularly in liquid form, face challenges with stability, leading to potential compounding errors, increased workload, and safety concerns due to their narrow therapeutic index and need for refrigeration, which complicates timely administration and increases the risk of adverse events.
Innovation Solution
Development of stable multi-dose liquid oral pharmaceutical compositions containing clonidine hydrochloride at 20 μg/mL, with pharmaceutically acceptable vehicles, stabilizers, and preservatives, ensuring stability for at least 6 months at various temperature and humidity conditions without significant potency loss or impurity formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If clonidine is formulated as a liquid oral composition, then ease of administration is improved, but stability deteriorates leading to compounding errors and safety concerns
Solution Approach 1:
The patent applies parameter changes by adjusting pH to a specific range (4-6) and controlling water activity through the choice of vehicle and excipients. These parameter modifications stabilize the clonidine molecule in liquid form, preventing degradation while maintaining ease of oral administration.
Solution Approach 2:
The patent introduces stabilizing agents and specific vehicle formulations as intermediaries between clonidine and the biological system. These intermediaries protect clonidine from degradation while allowing it to maintain its therapeutic activity and ease of administration.
2Reliability
If clonidine requires refrigeration for stability, then stability is improved, but ease of operation deteriorates due to storage complexity
Solution Approach 1:
The patent fundamentally changes the stability parameters of clonidine by formulating it in a liquid composition with controlled pH (4-6) and water activity. This allows the composition to remain stable at room temperature without requiring refrigeration, thereby maintaining stability while improving ease of storage and administration.
3Reliability
If liquid clonidine compositions are prepared frequently, then stability is maintained, but productivity deteriorates due to increased workload
Solution Approach 1:
The patent enables preliminary action by creating a stable liquid composition that can be prepared in advance and stored for extended periods without degradation. This eliminates the need for frequent preparation, reducing workload while maintaining stability through proper formulation with stabilizing agents and controlled pH.
4Reliability
If clonidine is administered at high concentration, then therapeutic effectiveness is improved, but safety deteriorates due to narrow therapeutic index
Solution Approach 1:
The patent replaces mechanical dosing precision with chemical stabilization mechanisms. By controlling pH and water activity in the liquid formulation, the patent ensures consistent drug performance and reduces variability in absorption, thereby improving therapeutic effectiveness while maintaining safety through more predictable pharmacokinetics.
Data Source
AI summary
The present invention relates to liquid pharmaceutical compositions of clonidine or its pharmaceutically acceptable salts thereof. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and are stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of clonidine at concentrations of 1 μg/mL or more are provided. The present invention further relates to stable oral liquid compositions of clonidine, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by clonidine.